OncoMatch/Clinical Trials/NCT03938987
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Is NCT03938987 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies autologous CD19-directed chimeric antigen receptor (CAR) T-cells for relapsed non hodgkin lymphoma.
Treatment: autologous CD19-directed chimeric antigen receptor (CAR) T-cells — Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
At least 2 prior systemic therapies
Cannot have received: immunotherapy directly targeting T-cells
Exception: anti-thymocyte globulin [ATG]
Prior treatment with immunotherapy directly targeting T-cells (except anti-thymocyte globulin [ATG])
Cannot have received: CD19-directed antibody-based therapies
Exception: blinatumomab
Prior treatment with ... CD19-directed antibody-based therapies (except blinatumomab)
Cannot have received: gene therapy products
Prior treatment with ... other gene therapy products
Cannot have received: investigational drug/anti-cancer therapy
Received any investigational drug/anti-cancer therapy within 30 days
Cannot have received: donor lymphocyte infusion
Donor lymphocyte infusion (DLI) within 4 weeks prior to leukapheresis
Cannot have received: salvage or debulking chemotherapy
Salvage or debulking chemotherapy within 1 week prior to blood collection for CAR T-cell product manufacture
Lab requirements
Kidney function
Cockroft-Gault creatinine clearance > 50 mL/min unless directly related to malignant disease being treated for on study
Liver function
total bilirubin < 1.5x ULN; and AST/ALT < 3x ULN unless directly related to malignant disease being treated for on study
Adequate renal function (defined as Cockroft-Gault creatinine clearance > 50 mL/min) and hepatic function (total bilirubin < 1.5x ULN; and AST/ALT < 3x ULN) unless directly related to malignant disease being treated for on study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify